News Headlines Article

New drug improves prognosis in advanced breast cancer cases
Los Angeles Daily News

A recent drug approval by the U.S. Food and Drug Administration is making waves in the breast cancer community.

The drug everolimus (brand name Afinitor, from drug manufacturer Novartis) has been approved as a treatment for postmenopausal women with advanced hormone receptor-positive, or HR+, breast cancer.

Everolimus is used in combination with the drug exemestane after failure of treatment with letrozole or anastrozole.